Case Series

Surgical Crown Lengthening in a Population With Human Immunodeficiency Virus: A Retrospective Analysis

Shilpa Kolhatkar,* Suzanne A. Mason,† Ana Janic,* Monish Bhola,* Shaziya Haque,‡ and James R. Winkler*

Background: Individuals with human immunodeficiency virus (HIV) have an increased risk of developing health problems, including some that are life threatening. Today, dental treatment for the population with a positive HIV diagnosis (HIV+) is comprehensive. There are limited reports on the outcomes of intraoral surgical therapy in patients with HIV, such as crown lengthening surgery (CLS) with osseous recontouring. This report investigates the outcome of CLS procedures performed at an urban dental school in a population of individuals with HIV. Specifically, this retrospective clinical analysis evaluates the healing response after CLS.

Methods: Paper and electronic records were examined from the year 2000 to the present. Twenty-one individuals with HIV and immunosuppression, ranging from insignificant to severe, underwent CLS. Pertinent details, including laboratory values, medications, smoking history/status, and postoperative outcomes, were recorded. One such surgery is described in detail with radiographs, photographs, and a videoclip.

Results: Of the 21 patients with HIV examined after CLS, none had postoperative complications, such as delayed healing, infection, or prolonged bleeding. Variations in viral load (<48 to 40,000 copies/mL), CD4 cell count (126 to 1,260 cells/mm³), smoking (6 of 21 patients), platelets (130,000 to 369,000 cells/mm³), and neutrophils (1.1 to 4.5 × 10³ /mm³) did not impact surgical healing. In addition, variations in medication regimens (highly active anti-retroviral therapy [18]; on protease inhibitors [1]; no medications [2]) did not have an impact.

Conclusions: The results of this retrospective analysis show the absence of postoperative complications after CLS in this population with HIV. Additional investigation into this area will help health care practitioners increase the range of surgical services provided to this group of patients. J Periodontol 2012;83:344-353.

KEY WORDS
Bone and bones; crown lengthening; facial bones; HIV; oral surgical procedures, preprosthetic.

* University of Detroit Mercy School of Dentistry, Department of Periodontics and Dental Hygiene, Detroit, MI.
† Graduate Periodontics Program at the University of Michigan, Ann Arbor, MI.
‡ Private practice, Odessa, TX.

indicates supplementary video in the online Journal of Periodontology.

The introduction of highly active antiretroviral therapy (HAART) has lead to reduction in the incidence of new acquired immune deficiency syndrome (AIDS) cases and the morbidity and mortality associated with human immunodeficiency virus infection (HIV).\(^1\)-\(^3\) In the initial stages of the HIV epidemic, dental treatment was focused on the management of HIV-associated oral lesions. Based on a survey of dental professionals’ attitudes toward the treatment of the population with HIV, some suggested that this population required treatment in specialized centers.\(^4\)

Other investigators have suspected this population to have higher complication rates after dental procedures but found no significant difference among individuals with HIV+ and HIV-negative status (HIV−).\(^5\)

Today, the population with HIV has the potential for an increased life expectancy as a result of advances in their overall care. Routine comprehensive care is often the primary dental need for well-managed patients with HIV. This treatment may include preprosthetic surgery, such as vestibuloplasty, soft-tissue grafting, implant placement, implant-related procedures, and crown lengthening (CLS).

According to a practice profile survey in 2003, CLS is one of the most common reasons for periodontal surgery.\(^6\) Restoring teeth to their proper anatomic form, function, and esthetics requires preparing a well-defined restorative margin. For example, this may not be obtainable in the presence of subgingival decay, crown/root fracture, or endodontic perforation. CLS makes the margins easily accessible for accurate impressions and ultimately results in good marginal adaptation of the restoration. In addition, CLS can achieve longer clinical crowns\(^7\)-\(^11\) and reestablish the biologic width\(^12\),\(^13\) by removal of hard and soft tissues.\(^14\)-\(^16\) The general consensus is that CLS should create ≥3 mm of sound tooth structure between the alveolar crest and the restorative margin.\(^17\)-\(^19\) Therefore, surgical intervention in the form of CLS is often necessary.\(^20\)

Reports of intraoral surgical procedures in a population with HIV are mainly limited to extractions,\(^21\)-\(^24\) implant placement,\(^25\)-\(^32\) and vestibuloplasty using palatal soft-tissue grafts.\(^33\) There are isolated reports of other periodontal surgical procedures, including the use of a lateral sliding flap and resin-modified glass ionomer for the management of an isolated recession defect.\(^34\)

To our knowledge, this is the first documentation that describes CLS with osseous recontouring in a population with HIV. In this retrospective analysis, only one individual had a CD4 count of <200 cells/mm\(^3\). The remaining 20 patients had immunosuppression levels that were generally mild (<500 cells/mm\(^3\) in eight patients) to no significant immunodeficiency (>500 cells/mm\(^3\) in 12 patients).\(^35\)

### MATERIALS AND METHODS

An 11-year retrospective analysis of paper and electronic records (Institutional Review Board #0910-23) at the University of Detroit Mercy School of Dentistry (UDMSOD), Detroit, MI, was conducted, and 21 individuals with HIV were identified who underwent CLS.

The HIV+ status of patients is based on self-reporting in the health history questionnaire and from the information provided by their treating physicians. Presurgical laboratory values for each patient consisted of the following: 1) CD4 cell count; 2) total white blood cell count (WBC); 3) viral load; 4) neutrophil, platelet count, hemoglobin, and hematocrit values. Other pertinent details, including medical history, medications, smoking status, and postoperative (PO) outcomes, were recorded. None of the patients required antibiotic prophylaxis, and none were prescribed antibiotics postoperatively.

All procedures were performed by periodontal faculty and periodontal residents at the UDMSOD under local anesthesia.\(^6\) PO management included written and verbal PO instructions and prescriptions for ibuprofen (600 or 800 mg; every 6 to 8 hours as needed for pain) and 0.12% chlorhexidine gluconate mouth rinse (15 mL; twice daily). All patients were seen at ≥1, 2, and 4 weeks PO for clinical evaluation.

Different factors were analyzed and compared relative to the surgical outcome. For example, maxillary versus mandibular, anterior versus posterior surgical site, males versus females, smoking status, duration of HIV+ status, and faculty versus resident performing the procedure were compared.

A detailed description of the presurgical preparation, surgical procedure, and PO healing of one case (#17) is provided below. The other CLS were performed in a similar manner with minor changes made to the flap design and amount of the bone removal necessary based on the clinical situation. A summary of all 21 cases can be found in Table 1.

### Detailed Description of the Procedure Performed in Case #17

A 62-year-old African American man was referred to the Graduate Periodontics Clinic at the UDMSOD. Recurrent subgingival decay was noted on the distal surfaces of both the first and second maxillary right premolars (Fig. 1). After caries removal and reevaluation, invasion of the biologic width was observed on teeth #4 and #5, and CLS was consequently indicated.

A review of the patient’s medical history indicated that he was diagnosed with HIV in 1987 and has since been regularly monitored by his physician. His medical history stated that he was positive for hepatitis B,
**Table 1. A Summary of Medical History, Laboratory Values, Medications, Surgical Dates, and Surgical Outcomes of 21 Cases**

<table>
<thead>
<tr>
<th>Patient's Sex, Age (Years)</th>
<th>Date of HIV Diagnosis</th>
<th>Other Medical Conditions/Smoking</th>
<th>HAART Treatment (Yes/No)</th>
<th>CD4 (×10^3/mm^3)</th>
<th>Viral Load (Copies/mL)</th>
<th>Neutrophils (×10^3/mm^3)</th>
<th>Total WBC (×10^3/mm^3)</th>
<th>Platelets (×10^3/mm^3)</th>
<th>Hemoglobin (g/dL)</th>
<th>Hematocrit (%)</th>
<th>Tooth #</th>
<th>Date of Crown Lengthening</th>
<th>Date of Restoration</th>
<th>Complications*</th>
<th>Medications</th>
<th>Osseous Surgery (Yes/No)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, 55</td>
<td>1992</td>
<td>History of non-Hodgkin's lymphoma, hip replacement, smoker</td>
<td>Yes</td>
<td>1.26</td>
<td>3,100</td>
<td>3.9</td>
<td>6.1</td>
<td>165</td>
<td>13.4</td>
<td>40</td>
<td>5, 6, 18</td>
<td>Apr 2003</td>
<td>May 2003</td>
<td>None</td>
<td>Aptivus, Norvir, Truvada</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 53</td>
<td>2003</td>
<td>Penicillin allergy, non-smoker</td>
<td>Yes</td>
<td>2.10</td>
<td>400</td>
<td>1.4</td>
<td>3.4</td>
<td>235</td>
<td>15.5</td>
<td>45.5</td>
<td>32</td>
<td>Feb 2005</td>
<td>Dec 2005</td>
<td>None</td>
<td>Atripla, Kaletra, Truvada</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 53</td>
<td>1984</td>
<td>Hepatitis B, non-smoker</td>
<td>Yes</td>
<td>2.40</td>
<td>40,000</td>
<td>2.5</td>
<td>5.9</td>
<td>202</td>
<td>13.1</td>
<td>39.1</td>
<td>30</td>
<td>Feb 2004</td>
<td>Mar 2004</td>
<td>None</td>
<td>Kaletra, Truvada</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 37</td>
<td>1993</td>
<td>Heart murmur, seasonal allergies, non-smoker</td>
<td>No</td>
<td>2.72</td>
<td>5,500</td>
<td>3.8</td>
<td>5.9</td>
<td>207</td>
<td>13.9</td>
<td>42.2</td>
<td>8</td>
<td>Feb 2004</td>
<td>Apr 2004</td>
<td>None</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 69</td>
<td>2007</td>
<td>Depression, hypertension, non-smoker</td>
<td>Yes</td>
<td>3.55</td>
<td>&lt;48</td>
<td>3.8</td>
<td>4.3</td>
<td>194</td>
<td>12.4</td>
<td>36.8</td>
<td>3</td>
<td>Jan 2009</td>
<td>Jan 2009</td>
<td>None</td>
<td>Reyataz, Norvir, Truvada</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 57</td>
<td>2004</td>
<td>Hepatitis B, smoker</td>
<td>Yes</td>
<td>3.70</td>
<td>&lt;48</td>
<td>2.6</td>
<td>5.4</td>
<td>189</td>
<td>17.8</td>
<td>51.2</td>
<td>31</td>
<td>Oct 2009</td>
<td>Jan 2010</td>
<td>None</td>
<td>Kaletra (Lopinavir/ Ritonavir), Truvada</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 44</td>
<td>2003</td>
<td>Penicillin allergy, non-smoker</td>
<td>Yes</td>
<td>3.73</td>
<td>248</td>
<td>1.3</td>
<td>4.2</td>
<td>227</td>
<td>14.6</td>
<td>44.2</td>
<td>31</td>
<td>Jul 2010</td>
<td>Dec 2010</td>
<td>None</td>
<td>Atripla</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 53</td>
<td>1983</td>
<td>None, non-smoker</td>
<td>Yes</td>
<td>4.00</td>
<td>2,000</td>
<td>1.1</td>
<td>3.7</td>
<td>130</td>
<td>14.5</td>
<td>40.7</td>
<td>14</td>
<td>Jan 2004</td>
<td>March 2004</td>
<td>None</td>
<td>Atripla, Reyataz</td>
<td>Yes</td>
</tr>
<tr>
<td>Female, 20</td>
<td>1991</td>
<td>Non-smoker</td>
<td>Yes</td>
<td>4.86</td>
<td>1,160</td>
<td>1.7</td>
<td>3.8</td>
<td>256</td>
<td>12</td>
<td>37</td>
<td>3</td>
<td>Mar 2010</td>
<td>Jul 2010</td>
<td>None</td>
<td>Truvada, Norvir, Reyataz</td>
<td>Yes</td>
</tr>
<tr>
<td>Female, 57</td>
<td>1993</td>
<td>Hepatitis B and C, one pack/day smoker</td>
<td>Yes</td>
<td>5.36</td>
<td>&lt;50</td>
<td>2.7</td>
<td>5.1</td>
<td>168</td>
<td>14.8</td>
<td>40.5</td>
<td>20</td>
<td>Apr 2002</td>
<td>Sep 2002</td>
<td>None</td>
<td>Combivir, Viralept</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 59</td>
<td>2001</td>
<td>Hypertension, non-smoker</td>
<td>Yes</td>
<td>5.74</td>
<td>&lt;48</td>
<td>2.8</td>
<td>5.2</td>
<td>219</td>
<td>13.9</td>
<td>41.7</td>
<td>31</td>
<td>Jan 2009</td>
<td>Jul 2009</td>
<td>None</td>
<td>Tenovir, Emtricitabine, Epaocom</td>
<td>Yes</td>
</tr>
</tbody>
</table>
**Table 1. (continued)**

A Summary of Medical History, Laboratory Values, Medications, Surgical Dates, and Surgical Outcomes of 21 Cases

<table>
<thead>
<tr>
<th>Patient’s Sex, Age (Years)</th>
<th>Date of HIV Diagnosis</th>
<th>Other Medical Conditions/Smoking</th>
<th>HAART Treatment (Yes/No)</th>
<th>CD4 (Cells/mm³)</th>
<th>Viral Load (Copies/mL)</th>
<th>Neutrophils (x10³/mm³)</th>
<th>Total WBC (x10³/mm³)</th>
<th>Platelets (x10³/mm³)</th>
<th>Hemoglobin (g/dL)</th>
<th>Hematocrit (%)</th>
<th>Tooth #</th>
<th>Date of Crown Lengthening</th>
<th>Date of Restoration</th>
<th>Complications*</th>
<th>Medications</th>
<th>Osseous Surgery (Yes/No)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, 42</td>
<td>2004</td>
<td>Depression, non-smoker</td>
<td>Yes</td>
<td>985</td>
<td>3,000</td>
<td>1.3</td>
<td>3.6</td>
<td>212</td>
<td>12.1</td>
<td>35.9</td>
<td>14, 15</td>
<td>Feb 2009</td>
<td>Nov 2009</td>
<td>None</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 40</td>
<td>2006</td>
<td>Smoker</td>
<td>Yes</td>
<td>585</td>
<td>&lt;50</td>
<td>6.2</td>
<td>6.1</td>
<td>351</td>
<td>15.4</td>
<td>n/a</td>
<td>3</td>
<td>Oct 2009</td>
<td>Dec 2009</td>
<td>None</td>
<td>Atripla</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 57</td>
<td>1991</td>
<td>Hepatitis B, non-smoker</td>
<td>Yes</td>
<td>612</td>
<td>&lt;40</td>
<td>2.7</td>
<td>7.3</td>
<td>198</td>
<td>18.3</td>
<td>52.4</td>
<td>3</td>
<td>Mar 2002</td>
<td>Apr 2002</td>
<td>None</td>
<td>Epivir; Ziagar, Viramune</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 63</td>
<td>2005</td>
<td>None, non-smoker</td>
<td>Yes</td>
<td>746</td>
<td>&lt;50</td>
<td>4.2</td>
<td>7.2</td>
<td>363</td>
<td>14.3</td>
<td>42.5</td>
<td>14,15</td>
<td>Jun 2008</td>
<td>May 2009</td>
<td>None</td>
<td>Kaletra, Truvada, Stativa (Efaviren)</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 36</td>
<td>1999</td>
<td>Smoker</td>
<td>Yes</td>
<td>779</td>
<td>&lt;48</td>
<td>1.8</td>
<td>5</td>
<td>242</td>
<td>14.2</td>
<td>44</td>
<td>31</td>
<td>Jan 2011, n/a</td>
<td>None</td>
<td>None</td>
<td>Atripla</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 64</td>
<td>1987</td>
<td>Latex and nickel allergy, hepatitis B, history of cocaine use, non-smoker</td>
<td>Yes</td>
<td>800</td>
<td>115</td>
<td>4.2</td>
<td>7.9</td>
<td>162</td>
<td>12.9</td>
<td>40.1</td>
<td>45</td>
<td>Nov 2008</td>
<td>Jan 2009</td>
<td>None</td>
<td>Kaletra</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 50</td>
<td>1985</td>
<td>Penicillin allergy, non-smoker</td>
<td>Yes</td>
<td>887</td>
<td>&lt;40</td>
<td>2.7</td>
<td>6</td>
<td>153</td>
<td>15.5</td>
<td>44.1</td>
<td>14</td>
<td>Jan 2011</td>
<td>Feb 2011</td>
<td>None</td>
<td>Indinavir, Reyatal, Nevipine, Norvir</td>
<td>Yes</td>
</tr>
<tr>
<td>Female, 39</td>
<td>2001</td>
<td>History of tuberculosis, asthma, smoker</td>
<td>Yes</td>
<td>1,046</td>
<td>&lt;75</td>
<td>1.7</td>
<td>4.7</td>
<td>197</td>
<td>13.5</td>
<td>40.4</td>
<td>4</td>
<td>Dec 2008</td>
<td>Mar 2009</td>
<td>None</td>
<td>Efaviren + Emtritabine + Tenofovir (Atripla)</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 49</td>
<td>2004</td>
<td>Knee joint replacement, herpes simplex 1, non-smoker</td>
<td>Yes</td>
<td>1,066</td>
<td>106</td>
<td>3.7</td>
<td>9.3</td>
<td>369</td>
<td>18.1</td>
<td>54.7</td>
<td>30</td>
<td>Apr 2008</td>
<td>Aug 2008</td>
<td>None</td>
<td>Tenofovir + Emtritabine (Truvada), Atazanavir, Ritonavir</td>
<td>Yes</td>
</tr>
<tr>
<td>Male, 45</td>
<td>1989</td>
<td>Hepatitis B and C, penicillin allergy, hypertension, non-smoker</td>
<td>Yes</td>
<td>1,240</td>
<td>160</td>
<td>2.2</td>
<td>6.5</td>
<td>294</td>
<td>15.1</td>
<td>42.8</td>
<td>28</td>
<td>Sept 2007</td>
<td>Nov 2007</td>
<td>None</td>
<td>Tenofovir, Tribuvir, Atazanavir (Reyatal), Alovacov, Ritonavir (Norvir)</td>
<td>No</td>
</tr>
</tbody>
</table>

* Prolonged bleeding, delayed healing, and/or infection.
sickle cell trait, and has an allergy to latex and nickel. He also had a history of cocaine use and smoking. The patient’s current medications included the protease inhibitors (lopinavir/ritonavir), an H2 receptor blocker (ranitidine), and an H1 receptor blocker (cetirizine). A review of the patient’s social history indicated married status. He had been an active patient at UDMSOD since 1975 and denied any significant changes in diet during the past 5 years.

A presurgical medical consultation was sent to the patient’s physician. The reported values are presented in Table 2.

### Table 2.
**Presurgical Laboratory Values for Case #17**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4+ T lymphocyte count</td>
<td>800 cells/mm³</td>
</tr>
<tr>
<td>Viral load</td>
<td>115 copies/mL</td>
</tr>
<tr>
<td>Neutrophil count</td>
<td>$4.2 \times 10^3$/mm³</td>
</tr>
<tr>
<td>WBC</td>
<td>$7.9 \times 10^3$/mm³</td>
</tr>
<tr>
<td>Platelet count</td>
<td>$162 \times 10^3$ cells/mm³</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>12.9 g/dL</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>40.1%</td>
</tr>
</tbody>
</table>

sickle cell trait, and has an allergy to latex and nickel. He also had a history of cocaine use and smoking. The patient’s current medications included the protease inhibitors (lopinavir/ritonavir), an H2 receptor blocker (ranitidine), and an H1 receptor blocker (cetirizine). A review of the patient’s social history indicated married status. He had been an active patient at UDMSOD since 1975 and denied any significant changes in diet during the past 5 years.

A presurgical medical consultation was sent to the patient’s physician. The reported values are presented in Table 2.

### Surgical Procedure

Written and oral informed consent for the surgical procedure was obtained, and the patient was educated regarding the surgical procedure and the PO healing and care. Profound anesthesia was obtained, and intrasulcular incisions were made on the facial and palatal surfaces of teeth #3 to #6. Extrasulcular incisions were made on the palatal surface of teeth #4 and #5 (Figs. 2A and 2B) (see supplementary video in the online *Journal of Periodontology*). A full-thickness flap was reflected facially and palatally. Ostectomy and osteoplasty were completed using hand and rotary instruments under copious irrigation. The presence of a bifurcation on the facial aspect of tooth #5 was noted and care was taken to minimize bone removal in the furcation area (Fig. 2C). The final topography of bone represented positive architecture with a knife-edged alveolar crest and the smooth transition of the bone level between adjacent teeth. A periodontal probe was used to confirm the presence of ≥3 mm of sound tooth structure coronal to the crest of bone on both premolars (Fig. 2D). The facial flap was apically positioned, and both flaps were sutured using 4-0 silk sutures (Figs. 2E and 2F). The provisional crowns were cemented on both premolars using temporary cement, and a periodontal dressing was placed over the surgical site. The patient was advised to take ibuprofen (600 mg as needed) and prescribed chlorhexidine gluconate rinse (0.12%; twice daily for 2 weeks). The patient was asked to refrain from brushing the surgical area and chewing on the right side and was seen for PO appointments at 1, 3, and 4 weeks.

### PO Healing Pattern

At the 1-week PO visit, the dressing and all remaining sutures were removed. The surgical site appeared to be healing well and the patient reported no post-surgical concerns. He was asked to clean the surgical area using an extra soft surgical toothbrush. The patient was then seen at 3 weeks PO, and the presence of slight erythema on the palatal gingiva was observed in the region of the premolars. Oral hygiene instructions were reinforced. The patient was seen again at 4 weeks PO and uneventful healing was observed (Fig. 3A). Approximately 12 weeks post-surgery, porcelain-fused-to-metal crowns were cemented on both premolars (Figs. 3B and 3C). For the next 2 years, the patient was seen regularly for routine dental care. At the 2-year follow-up, the patient exhibited pink healthy gingiva on teeth #4 and #5 with no visible signs of inflammation, bleeding on probing, or plaque accumulation. The gingival contour was firm and knife-edged (Fig. 4A). The bitewing and periapical radiograph revealed no evidence of recurrent caries.

---

4-0 silk suture, Ethicon, Somerville, NJ.

Temp-Bond NE (Non-Eugenol) Accelerator, Kerr, Orange, CA.

COE-PAK, GC America, Alsip, IL.

0.12% chlorhexidine gluconate, 3M ESPE, St. Paul, MN.

GUM, Sunstar Americas, Chicago, IL.
marginal discrepancies, or periapical pathologies on teeth #4 and #5 (Figs. 4B and 4C).

RESULTS
The evaluation of the data from the 21 cases shows no complications with regard to delayed healing, prolonged bleeding, or infections. Most patients were seen at 1, 2, and 4 weeks PO, and almost all were treated by residents (19 of 21). The teeth were predominantly posterior (19 of 21), with an equal distribution between the two arches (10 CLS teeth were in the mandible and 11 in the maxilla).

Figure 2.
A) Intraseulcular incision on the facial surfaces of teeth #3 to #6. B) Extraseulcular incisions were made on the palatal surface of teeth #3 and #6. C) The presence of a bifurcation (black arrow) on the facial aspect of #5 was observed after flap reflection. D) The presence of ≥3 mm of sound tooth structure on both premolars was confirmed. E) Facial view of apically positioned flap. F) Palatal view after sutures were placed.
Figure 3.
A) Good oral hygiene seen around provisional crowns at the 4-week PO visit. B) Healthy gingiva with an absence of plaque and inflammation seen before cementation of definitive crowns. C) Facial view of definitive crowns cemented 12 weeks after CLS.

Figure 4.
A) Two-year PO facial view. B) Two-year bitewing radiograph showing no recurrent carious lesions. C) Two-year periapical radiograph showing maintenance of biologic width and crestal bone level.
The patients were predominantly male (17 of 21). At the time of surgery, the duration of HIV+ diagnosis ranged from 1 to 21 years (five were diagnosed in the 1980s, six in the 1990s, and 10 in the 2000s). Most of the patients were non-smokers (15 of 21), five were light smokers, and one was a heavy smoker. Despite the effect of smoking on periodontal wound healing, smoking did not appear to have an effect in the cases presented here.36-38

It is also important to note that the variations in viral load (<48 to 40,000 copies/mL), CD4 cell count (126 to 1,260 cells/mm<sup>3</sup>), platelets (130,000 to 369,000 cells/mm<sup>3</sup>), and neutrophils (1.1 to 4.5 × 10<sup>3</sup>/mm<sup>3</sup>) did not impact surgical healing. Based on CD4 counts, the levels of immunosuppression were insignificant in 12 individuals (>500 cells/mm<sup>3</sup>), mild in five individuals (350 to 499 cells/mm<sup>3</sup>), advanced in three individuals (200 to 349 cells/mm<sup>3</sup>), and severe in one individual (<200 cells/mm<sup>3</sup>).35 Of the 21 patients, 18 were on HAART, one only on protease inhibitors, and two were taking no medications for HIV at the time of surgery. This variation in medication regimens also did not appear to have an impact on wound healing.

**DISCUSSION**

Oral manifestations are a classic component of the AIDS epidemic.1 The discovery of HAART has brought substantial benefits to the population with HIV, such as improvements in their quality of life, increased life expectancy, and a dramatic decrease in oral manifestations of the disease.1-3 Today, the dental needs of patients with HIV are consistent with the comprehensive dental care needs seen in the general population. Although antiretroviral medications are a mainstay in the management of HIV, they may have some adverse effects on the oral environment. A study that looked at long-term antiretroviral medication use found a reduction in salivary flow that may indirectly contribute to increased caries risk.39,40 The need for CLS in the presence of recurrent subgingival decay was described in Case 17.

HIV infection does not appear to be a risk factor for tooth loss according to a retrospective cross-sectional study that involved 193 HIV+ patients and 192 systemically healthy patients.24 Using matched controls, comparing individuals with HIV+ to HIV− status, the results showed that age, race, and smoking status were all risk factors for tooth loss, but CD4+ cell count and viral load in the HIV+ patients did not influence tooth loss. The authors concluded that individuals with HIV treated with HAART are not at an increased risk for tooth loss when compared to systemically healthy individuals. Based on the fact that individuals with HIV are enjoying a longer lifespan and retaining their dentition for longer periods of time, we can expect this population to need treatment such as vestibuloplasty, soft-tissue grafting, implant placement, implant-related procedures, and CLS. This case series may be beneficial because it is describing a similar procedure (CLS) in a large group of individuals with HIV.

Most studies and clinical experience show that all patients, including healthy individuals, are susceptible to post-treatment complications when undergoing surgical dental care. Comparisons of surgical complications between populations with HIV+ and HIV− status are scarce. Glick3 conducted a retrospective study on 331 patients with HIV, with suppressed immune systems (CD4 counts of <200 cells/mm<sup>3</sup>). These patients underwent 1,810 common invasive dental procedures, including periodontal, restorative, endodontic, prosthodontic, and surgical procedures. These procedures were performed by general dentists and had a low overall complication rate of only 0.9%. When we examined the complication rate after surgical tooth extractions, we found it to be similar for individuals with both HIV+ and HIV− status.5 Campo et al. evaluated post-treatment complications in 101 patients with HIV. The overall complication rate in these patients was found to be 2.2% and 4.8% after invasive dental procedures. No relationship was found among complications and virologic, immunologic, or other laboratory values.21 In another study, a similar percentage (3.7% versus 2.9%) of postextraction complications is seen in patients with both HIV+ and HIV− status.16 A prospective study by Dodson22 reported no differences in the complication rates between patients with HIV+ and HIV− status who underwent tooth extraction. Similarly, in our study, there were no complications noted in patients with HIV whose viral loads varied from non-detectable to 40,000 copies/mL. In our patient population, immunosuppression levels ranged from insignificant to severe and did not impact the PO wound healing. The experience of the operator did not appear to have any impact because the majority of the CLS in our series were performed by residents.

A PO complication that has been studied is the occurrence of infection in the surgical area. One of the major reasons why invasive dental procedures are not attempted on individuals with HIV is the presumption that they are more susceptible to infections and complications after such procedures.23 Occasional reports have suggested that the patients with HIV may present a higher risk for PO infections after maxillofacial trauma surgery compared to individuals with HIV− status. A study41 showed that in the case of mandibular fractures, preoperative infection rates were statistically significant (26.4% versus 6.5% for HIV+ versus HIV−). Although PO infections were higher in cases with HIV+ than cases with HIV− status, this difference was not statistically significant.

Most of the above cited authors agree that the rate of complications in patients with HIV is similar in all stages of the disease, including those with CD4+ lymphocyte loads.
counts of <200 cells/mm\(^3\). One of the cases presented here had a CD4+ count of 126 cells/mm\(^3\), but it did not seem to influence the outcome of CLS.

Dental surgical procedures, such as CLS, which involves manipulation of periodontal tissues, is commonly associated with transient bacteremias. It is not standard protocol to administer prophylactic antibiotics to prevent septicemia from bacteremias arising from invasive dental procedures based solely on the patient’s HIV status; however, antibiotic prophylaxis is indicated for severely neutropenic patients with absolute neutrophil counts that are <500 cells/mm\(^3\). A systematic review by Patton et al.\(^\text{15}\) also concluded that HIV status alone is not an indication for the routine use of antibiotic prophylaxis before dental treatment. In the five studies that were reviewed, it was found that PO complications in the patients with HIV were minor, and treatment was done on an outpatient basis. Furthermore, none of the five studies suggested the necessity for special precautions, such as administration of antibiotic prophylaxis based solely on the patient’s HIV status. Based on the available evidence, no preoperative antibiotics were prescribed in the cases presented here.

CONCLUSIONS
Currently available treatment for the population with HIV/AIDS and a longer life expectancy has resulted in the need for more comprehensive dental treatment of patients with HIV. These procedures include preprosthetic, orthodontic, and periodontal surgical procedures. The evaluation of the data from the 21 cases presented here showed that there were no complications with regard to delayed healing, prolonged bleeding, or infections after CLS in this population with HIV. Smoking status did not have an impact on the occurrence of the complications, although 25% (six of 21) of the patients were light smokers. We anticipate that this case series will help demonstrate that a commonly performed periodontal surgical procedure, such as CLS, is safe and predictable in the population with HIV.

ACKNOWLEDGMENTS
The authors thank Mr. Eric Jacobs, media specialist, School of Dentistry, University of Detroit Mercy (UDM), Detroit, MI. They also acknowledge Dr. Tanya Saour (former student at UDM), Dr. Melanie Mayberry (Clinic Director of Predoctoral Clinic Care, University Health Center), and Dr. Mary Parise (Program Director, Advanced Education in General Dentistry [AEGD] at UDM). The authors report no conflicts of interest related to this case series.

REFERENCES

Correspondence: Dr. Shilpa Kolhatkar, 2700 Martin Luther King Jr. Blvd., Detroit, MI 48208-2576. Fax: 313/494-6666; e-mail: kolhatsh@udmercy.edu.

Submitted May 26, 2011; accepted for publication July 4, 2011.